Risk factors for COVID-19 diagnosis, hospitalization, and subsequent all-cause mortality in Sweden: a nationwide study.
Adolescent
Adult
Age Factors
Aged
Aged, 80 and over
COVID-19
/ diagnosis
Comorbidity
Female
Hospitalization
/ statistics & numerical data
Humans
Intensive Care Units
/ statistics & numerical data
Male
Middle Aged
Mortality
/ trends
Residential Facilities
/ statistics & numerical data
Risk Factors
SARS-CoV-2
Sex Factors
Socioeconomic Factors
Sweden
/ epidemiology
Young Adult
COVID-19
Case–control study
Cohort study
Coronavirus
Epidemiology
SARS-CoV-2
Journal
European journal of epidemiology
ISSN: 1573-7284
Titre abrégé: Eur J Epidemiol
Pays: Netherlands
ID NLM: 8508062
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
08
01
2021
accepted:
13
02
2021
pubmed:
12
3
2021
medline:
22
4
2021
entrez:
11
3
2021
Statut:
ppublish
Résumé
We conducted a nationwide, registry-based study to investigate the importance of 34 potential risk factors for coronavirus disease 2019 (COVID-19) diagnosis, hospitalization (with or without intensive care unit [ICU] admission), and subsequent all-cause mortality. The study population comprised all COVID-19 cases confirmed in Sweden by mid-September 2020 (68,575 non-hospitalized, 2494 ICU hospitalized, and 13,589 non-ICU hospitalized) and 434,081 randomly sampled general-population controls. Older age was the strongest risk factor for hospitalization, although the odds of ICU hospitalization decreased after 60-69 years and, after controlling for other risk factors, the odds of non-ICU hospitalization showed no trend after 40-49 years. Residence in a long-term care facility was associated with non-ICU hospitalization. Male sex and the presence of at least one investigated comorbidity or prescription medication were associated with both ICU and non-ICU hospitalization. Three comorbidities associated with both ICU and non-ICU hospitalization were asthma, hypertension, and Down syndrome. History of cancer was not associated with COVID-19 hospitalization, but cancer in the past year was associated with non-ICU hospitalization, after controlling for other risk factors. Cardiovascular disease was weakly associated with non-ICU hospitalization for COVID-19, but not with ICU hospitalization, after adjustment for other risk factors. Excess mortality was observed in both hospitalized and non-hospitalized COVID-19 cases. These results confirm that severe COVID-19 is related to age, sex, and comorbidity in general. The study provides new evidence that hypertension, asthma, Down syndrome, and residence in a long-term care facility are associated with severe COVID-19.
Identifiants
pubmed: 33704634
doi: 10.1007/s10654-021-00732-w
pii: 10.1007/s10654-021-00732-w
pmc: PMC7946619
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
287-298Références
Phelan AL, Katz R, Gostin LO. The novel coronavirus originating in Wuhan, China: challenges for global health governance. JAMA. 2020;323:709–10.
doi: 10.1001/jama.2020.1097
World Health Organization. Listings of WHO’s response to COVID-19. https://www.who.int/news/item/29-06-2020-covidtimeline . Accessed 21 Dec 2020.
Tian H, Liu Y, Li Y, et al. An investigation of transmission control measures during the first 50 days of the COVID-19 epidemic in China. Science. 2020;368:638–42.
doi: 10.1126/science.abb6105
Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020;369:m1985.
doi: 10.1136/bmj.m1985
Kim L, Garg S, O’Halloran A, et al. Risk factors for intensive care unit admission and in-hospital mortality among hospitalized adults identified through the US Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET). Clin Infect Dis. 2020;2:16.
Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020;369:m1966.
doi: 10.1136/bmj.m1966
Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584:430–6.
doi: 10.1038/s41586-020-2521-4
Reilev M, Kristensen KB, Pottegård A, et al. Characteristics and predictors of hospitalization and death in the first 11 122 cases with a positive RT-PCR test for SARS-CoV-2 in Denmark: a nationwide cohort. Int J Epidemiol. 2020;49:1468–81.
doi: 10.1093/ije/dyaa140
Cummings MJ, Baldwin MR, Abrams D, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet. 2020;395:1763–70.
doi: 10.1016/S0140-6736(20)31189-2
Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–20.
doi: 10.1056/NEJMoa2002032
Fosbøl EL, Butt JH, Østergaard L, et al. Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality. JAMA. 2020;324:168–77.
doi: 10.1001/jama.2020.11301
Barron E, Bakhai C, Kar P, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol. 2020;8:813–22.
doi: 10.1016/S2213-8587(20)30272-2
Brooke HL, Talbäck M, Hörnblad J, et al. The Swedish cause of death register. Eur J Epidemiol. 2017;32:765–73.
doi: 10.1007/s10654-017-0316-1
Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450.
doi: 10.1186/1471-2458-11-450
Barlow L, Westergren K, Holmberg L, et al. The completeness of the Swedish Cancer Register-a sample survey for year 1998. Acta Oncol (Madr). 2009;48:27–33.
doi: 10.1080/02841860802247664
Wettermark B, Hammar N, MichaelFored C, et al. The new Swedish Prescribed Drug Register—opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf. 2007;16:726–35.
doi: 10.1002/pds.1294
Kroksgård A. Kvalitetsdeklaration-statistik om socialtjänstinsatser till äldre 2019. Stockholm [SE]: Socialstyrelsen; 2020. https://www.socialstyrelsen.se/globalassets/sharepoint-dokument/artikelkatalog/statistik/2020-4-6745-kvalitetsdeklaration.pdf
Svenska Intesivvårdsregistret. Svenska Intesivvårdsregistret Årsrapport 2019. 2020. https://www.icuregswe.org/globalassets/arsrapporter/arsrapport_2019_final.pdf
Statistiska centralbyrån. Befolkning efter ålder och kön. År 1860–2019. https://www.statistikdatabasen.scb.se/pxweb/sv/ssd/START__BE__BE0101__BE0101A/BefolkningR1860/ #. Accessed 27 Nov 2020.
Clift A, Coupland C, Keogh R, et al. COVID-19 mortality risk in Down syndrome: results from a cohort study of 8 million adults. Ann Intern Med. 2020;21:20–4986.
Mancia G, Rea F, Ludergnani M, et al. Renin–angiotensin–aldosterone system blockers and the risk of COVID-19. N Engl J Med. 2020;382:2431–40.
doi: 10.1056/NEJMoa2006923
Mehta N, Kalra A, Nowacki AS, et al. Association of use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5:1020–6.
doi: 10.1001/jamacardio.2020.1855
Cohen JB, Hanff TC, William P, et al. Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial. Lancet Respir Med. 2021;S2213–2600(20):30558.
Lopes RD, Macedo AVS, de Barros E, Silva PGM, et al. Effect of discontinuing vs continuing angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on days alive and out of the hospital in patients admitted with COVID-19: a randomized clinical trial. JAMA. 2021;325:254–64.
doi: 10.1001/jama.2020.25864
Wang Z, Deng H, Ou C, et al. Clinical symptoms, comorbidities and complications in severe and non-severe patients with COVID-19: a systematic review and meta-analysis without cases duplication. Medicine (Baltimore). 2020;99:e23327.
doi: 10.1097/MD.0000000000023327
Bae S, Kim SR, Kim M-N, et al. Impact of cardiovascular disease and risk factors on fatal outcomes in patients with COVID-19 according to age: a systematic review and meta-analysis. Heart. 2020;5:1–8.
Zheng Z, Peng F, Xu B, et al. Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis. J Infect. 2020;81:e16-25.
doi: 10.1016/j.jinf.2020.04.021
Burki T. England and Wales see 20 000 excess deaths in care homes. Lancet. 2020;395:1602.
doi: 10.1016/S0140-6736(20)31199-5
pubmed: 32446403
pmcid: 7241982
Folkhälsomyndigheten. Uppdrag för utökad diagnostik av covid-19. https://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2020/mars/uppdrag-for-utokad-diagnostik-av-covid-19/ . Accessed 21 Dec 2020.
Folkhälsomyndigheten. Nationell strategi för att utöka provtagningen för covid-19. https://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2020/april/nationell-strategi-for-att-utoka-provtagningen-for-covid-19/ . Accessed 21 Dec 2020.
Regeringen. Regeringen satsar 5,9 miljarder på utökad testning och smittspårning. https://www.regeringen.se/pressmeddelanden/2020/06/regeringen-satsar-59-miljarder-pa-utokad-testning-och-smittsparning/ . Accessed 21 Dec 2020.